Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.

× No keyword cloud information.

14 in total

1. N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.

Authors: Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Jie Yang; Jessica E Thorpe; Michael A Ihnat
Journal: Bioorg Med Chem Date: 2012-02-04 Impact factor: 3.641

2. Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.

Authors: Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Bryan C Disch; Jessica E Thorpe; Anja Bastian; Michael A Ihnat
Journal: Bioorg Med Chem Date: 2013-01-31 Impact factor: 3.641

3. Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck.

Authors: Amit Bahl; Naresh Kumar Panda; Arun Elangovan; Jaimanti Bakshi; Roshan Verma; Satyawati Mohindra; Rijuneeta Gupta; Arun Singh Oinam; Satinder Kaur; R K Vashishta; Sushmita Ghoshal
Journal: Indian J Otolaryngol Head Neck Surg Date: 2018-07-07

4. Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.

Authors: Xiaojun Lu; Xingbo Song; Yuanxin Ye; Xianzhong Liu; Yi Zhou; Lei Zhang; Jun Wang; Binwu Ying; Lanlan Wang
Journal: Mol Biol Rep Date: 2010-02-02 Impact factor: 2.316

Review 5. Acquired Resistance to Drugs Targeting Tyrosine Kinases.

Authors: Steven A Rosenzweig
Journal: Adv Cancer Res Date: 2018-03-02 Impact factor: 6.242

6. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.

Authors: Ridvan Ali; Fahir Ozkalemkas; Vildan Ozkocaman; Tahsin Yakut; Hulya Ozturk Nazlioglu; Ferah Budak; Murat Pekgoz; Serhat Korkmaz; Mutlu Karkucak; Tulay Ozcelik; Ahmet Tunali
Journal: Int J Clin Oncol Date: 2009-12-05 Impact factor: 3.402

7. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.

Authors: Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Lora C Bailey-Downs
Journal: Bioorg Med Chem Date: 2013-01-10 Impact factor: 3.641

8. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.

Authors: Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Linda A Warnke
Journal: Bioorg Med Chem Date: 2008-04-14 Impact factor: 3.641

9. Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST).

Authors: Komal Wasif; Nawal Wasif; Muhammad W Saif
Journal: Cureus Date: 2016-10-26

10. Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation.

Authors: Jesus Paez-Mayorga; Andrew L Chen; Sivareddy Kotla; Yunting Tao; Rei J Abe; Emma D He; Brian P Danysh; Marie-Claude C Hofmann; Nhat-Tu Le
Journal: Front Cardiovasc Med Date: 2018-09-06